Exploring Emerging Cell Sources & Platform Technologies to Expand Sourcing Options & Reduce Supply Constraints
4:15 pm - Tuesday 8th December 2026
- Evaluating iPSC-derived cell products as alternative sources that enable single-clone, single-donor strategies with unlimited expansion potential
- Assessing cord blood versus PBMC versus bone marrow sourcing trade-offs based on cell content, engraftment kinetics and manufacturing requirements
- Investigating whether iPSC platforms will fundamentally reshape donor selection by shifting focus to optimal source material for iPSC generation
